Login to Your Account



Chelsea’s $21.5M To Fund Proof-Of-Concept Studies

By Karen Pihl-Carey


Wednesday, February 15, 2006
Two-year-old Chelsea Therapeutics International Ltd. completed its second major financing, raising $21.5 million in a private placement of common stock that will bring its sole clinical-stage product, CH-1504, through Phase II studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription